Drug Profile
Research programme: human monoclonal antibody therapeutics - diaDexus/Medarex
Alternative Names: Human monoclonal antibody therapeutics research programme - diaDexus/MedarexLatest Information Update: 30 Jul 2010
Price :
$50
*
At a glance
- Originator diaDexus; Medarex
- Developer diaDexus Inc; Medarex
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Lung cancer; Ovarian cancer
Most Recent Events
- 28 Jul 2010 diaDexus has been acquired by VaxGen
- 31 May 2010 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 31 May 2010 Discontinued - Preclinical for Ovarian cancer in USA (Parenteral)